{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:28:53Z","timestamp":1790803733765,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sarcoidosis is a heterogenous, multi-systemic granulomatous disease with highly variable incidence (5\u201340\/100,000) and a disproportionate mortality burden in those presented with pulmonary fibrosis or cardiac involvement. Yet, current management strategies are symptom-targeting, not always effective and come with significant side effects. Preclinical murine models of sarcoidosis have shown that aberrant mTORC1 activation promotes macrophage-driven inflammation and disrupts autophagic clearance, sustaining granuloma formation. Sirolimus, a selective mTORC1 inhibitor, restores autophagy and macrophage function, offering a targeted therapeutic approach. Herein, we present the first comprehensive review of all known clinical cases of sirolimus use in different forms of sarcoidosis. All studies reviewed suggest that sirolimus may be an effective, yet safe, mechanism-targeting therapy for patients with sarcoidosis not responding to conventional pharmacological interventions.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s12265-025-10700-4","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:07:57Z","timestamp":1758809277000},"page":"1893-1901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Use of Sirolimus, an mTOR Inhibitor, to Treat Sarcoidosis in Multiple Systems"],"prefix":"10.1007","volume":"18","author":[{"given":"Liam","family":"McGuire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxxy","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-6870","authenticated-orcid":false,"given":"Angeliki","family":"Asimaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"issue":"4","key":"10700_CR1","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.it.2020.01.007","volume":"41","author":"Y Pacheco","year":"2020","unstructured":"Pacheco Y, Lim CX, Weichhart T, Valeyre D, Bentaher A, Calender A. Sarcoidosis and the mTOR, Rac1, and autophagy triad. Trends Immunol. 2020;41(4):286\u201399.","journal-title":"Trends Immunol"},{"key":"10700_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152102","volume":"57","author":"MC Baker","year":"2022","unstructured":"Baker MC, Vago E, Liu Y, Lu R, Tamang S, Horvath-Puho E, et al. Sarcoidosis incidence after mTOR inhibitor treatment. Semin Arthritis Rheum. 2022;57:152102.","journal-title":"Semin Arthritis Rheum"},{"issue":"19","key":"10700_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030478","volume":"12","author":"C Bueno-Beti","year":"2023","unstructured":"Bueno-Beti C, Lim CX, Protonotarios A, Szabo PL, Westaby J, Mazic M, et al. An mTORC1-dependent mouse model for cardiac sarcoidosis. J Am Heart Assoc. 2023;12(19):e030478.","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10700_CR4","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.cardfail.2024.10.444","volume":"31","author":"D Richards","year":"2025","unstructured":"Richards D, Fujito H, Shanbhag A, Akhavan B, Frame E, Hayes S, et al. Utility of mechanistic target of rapamycin inhibitors in cardiac sarcoidosis. J Card Fail. 2025;31(7):1032\u20136.","journal-title":"J Card Fail"},{"issue":"18","key":"10700_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12186088","volume":"12","author":"MA Judson","year":"2023","unstructured":"Judson MA. The symptoms of pulmonary sarcoidosis. J Clin Med. 2023;12(18):6088.","journal-title":"J Clin Med"},{"key":"10700_CR6","unstructured":"Hussain K, Shetty M. Cardiac Sarcoidosis. In: StatPearls. Treasure Island (FL). 2025. Available from: NCBI Bookshelf, Bookshelf ID NBK578192."},{"issue":"5","key":"10700_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/MCP.0000000000000715","volume":"26","author":"EV Arkema","year":"2020","unstructured":"Arkema EV, Cozier YC. Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors. Curr Opin Pulm Med. 2020;26(5):527\u201334.","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"10700_CR8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1378\/chest.10-0413","volume":"139","author":"YC Cozier","year":"2011","unstructured":"Cozier YC, Berman JS, Palmer JR, Boggs DA, Serlin DM, Rosenberg L. Sarcoidosis in black women in the United States: data from the Black Women\u2019s Health Study. Chest. 2011;139(1):144\u201350.","journal-title":"Chest"},{"key":"10700_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.545413","volume":"11","author":"AK Gerke","year":"2020","unstructured":"Gerke AK. Treatment of sarcoidosis: a multidisciplinary approach. Front Immunol. 2020;11:545413.","journal-title":"Front Immunol"},{"key":"10700_CR10","unstructured":"Hodgens A, Sharman T. Corticosteroids. In: StatPearls. Treasure Island (FL). 2025. Available from: NCBI Bookshelf, Bookshelf ID NBK554612."},{"issue":"3","key":"10700_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/17476348.2017.1289842","volume":"11","author":"ML Ribeiro Neto","year":"2017","unstructured":"Ribeiro Neto ML, Culver DA. Sarcoidosis: treatments beyond prednisone and methotrexate. Expert Rev Respir Med. 2017;11(3):167\u201370.","journal-title":"Expert Rev Respir Med"},{"issue":"16","key":"10700_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612792","volume":"24","author":"R Kraaijvanger","year":"2023","unstructured":"Kraaijvanger R, Ambarus CA, Damen J, van der Vis JJ, Kazemier KM, Grutters JC, et al. Simultaneous assessment of mTORC1, JAK\/STAT, and NLRP3 inflammasome activation pathways in patients with sarcoidosis. Int J Mol Sci. 2023;24(16):12792.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10700_CR13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","volume":"174","author":"RP Baughman","year":"2006","unstructured":"Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795\u2013802.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10700_CR14","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.jaad.2012.10.056","volume":"68","author":"RJ Pariser","year":"2013","unstructured":"Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765\u201373.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10700_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.semarthrit.2012.10.008","volume":"43","author":"E Russell","year":"2013","unstructured":"Russell E, Luk F, Manocha S, Ho T, O\u2019Connor C, Hussain H. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy. Semin Arthritis Rheum. 2013;43(1):119\u201324.","journal-title":"Semin Arthritis Rheum"},{"key":"10700_CR16","first-page":"CD008794","volume":"2","author":"JA Singh","year":"2011","unstructured":"Singh JA, Wells GA, Christensen R, TanjongGhogomu E, Maxwell L, Macdonald JK, et al. 2011 Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2:CD008794.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10700_CR17","first-page":"378","volume":"11","author":"A Decock","year":"2017","unstructured":"Decock A, Van Assche G, Vermeire S, Wuyts W, Ferrante M. Sarcoidosis-Like Lesions: Another Paradoxical Reaction to Anti-TNF Therapy? J Crohns Colitis. 2017;11(3):378\u201383.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10700_CR18","first-page":"203","volume":"14","author":"W Ericson-Neilsen","year":"2014","unstructured":"Ericson-Neilsen W, Kaye AD. Steroids: pharmacology, complications, and practice delivery issues. Ochsner J. 2014;14(2):203\u20137.","journal-title":"Ochsner J"},{"key":"10700_CR19","unstructured":"Gerriets V, Goyal A, Khaddour K. Tumor Necrosis Factor Inhibitors. In: StatPearls. Treasure Island (FL). 2025. Available from: NCBI Bookshelf, Bookshelf ID NBK482425."},{"issue":"1","key":"10700_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01608-z","volume":"8","author":"V Panwar","year":"2023","unstructured":"Panwar V, Singh A, Bhatt M, Tonk RK, Azizov S, Raza AS, et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther. 2023;8(1):375.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10700_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10286-019-00662-4","volume":"30","author":"A Ndayisaba","year":"2020","unstructured":"Ndayisaba A, Wenning GK. Inhibition of the mammalian target or rapamycin (mTOR): a potential therapeutic strategy for multiple system atrophy. Clin Auton Res. 2020;30(1):7\u20138.","journal-title":"Clin Auton Res"},{"issue":"3","key":"10700_CR22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/ni.3655","volume":"18","author":"M Linke","year":"2017","unstructured":"Linke M, Pham HT, Katholnig K, Schnoller T, Miller A, Demel F, et al. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol. 2017;18(3):293\u2013302.","journal-title":"Nat Immunol"},{"issue":"5","key":"10700_CR23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCEP.111.964890","volume":"4","author":"A Asimaki","year":"2011","unstructured":"Asimaki A, Tandri H, Duffy ER, Winterfield JR, Mackey-Bojack S, et al. Altered desmosomal proteins in granulomatous myocarditis and potential pathogenis links to arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2011;4(5):743\u201352.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"18","key":"10700_CR24","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1161\/CIRCULATIONAHA.119.040676","volume":"140","author":"SP Chelko","year":"2019","unstructured":"Chelko SP, Asimaki A, Lowenthal J, Bueno-Beti C, Bedja D, Scalco A, et al. Therapeutic modulation of the immune response in arrhythmogenic cardiomyopathy. Circulation. 2019;140(18):1491\u2013505.","journal-title":"Circulation"},{"issue":"10","key":"10700_CR25","doi-asserted-by":"publisher","first-page":"721","DOI":"10.7164\/antibiotics.28.721","volume":"28","author":"C Vezina","year":"1975","unstructured":"Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975;28(10):721\u20136.","journal-title":"J Antibiot (Tokyo)"},{"issue":"8","key":"10700_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-235372","volume":"13","author":"KJ Kelleher","year":"2020","unstructured":"Kelleher KJ, Russell J, Killeen OG, Leahy TR. Treatment-recalcitrant laryngeal sarcoidosis responsive to sirolimus. BMJ Case Rep. 2020;13(8):e235372.","journal-title":"BMJ Case Rep"},{"issue":"6","key":"10700_CR27","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/00007691-199512000-00019","volume":"17","author":"SN Sehgal","year":"1995","unstructured":"Sehgal SN. Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit. 1995;17(6):660\u20135.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10700_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","volume":"22","author":"DD Sarbassov","year":"2006","unstructured":"Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB. Mol Cell. 2006;22(2):159\u201368.","journal-title":"Mol Cell"},{"issue":"6","key":"10700_CR29","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1002\/j.1875-9114.1997.tb03080.x","volume":"17","author":"PA Kelly","year":"1997","unstructured":"Kelly PA, Gruber SA, Behbod F, Kahan BD. Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy. 1997;17(6):1148\u201356.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10700_CR30","first-page":"259","volume":"32","author":"M Faehling","year":"2015","unstructured":"Faehling M, Wienhausen-Wilke V, Fallscheer S, Trinajstic-Schulz B, Weber J, Leschke M. Long-term stable lung function and second uncomplicated pregnancy on sirolimus in lymphangioleiomyomatosis (LAM). Sarcoidosis Vasc Diffuse Lung Dis. 2015;32(3):259\u201364.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"9","key":"10700_CR31","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1164\/rccm.202004-0914IM","volume":"202","author":"N Gupta","year":"2020","unstructured":"Gupta N, Bleesing JH, McCormack FX. Successful response to treatment with sirolimus in pulmonary sarcoidosis. Am J Respir Crit Care Med. 2020;202(9):e119\u201320.","journal-title":"Am J Respir Crit Care Med"},{"issue":"14","key":"10700_CR32","first-page":"103633","volume":"30","author":"R Brown","year":"2025","unstructured":"Brown R, Macrohon-Sabaitue S, Specterman M, Asimaki A. Multisystemic, possibly familial sarcoidosis ameliorated by an mTOR inhibitor. JACC: Case Reports. 2025;30(14):103633.","journal-title":"JACC: Case Reports"},{"issue":"8","key":"10700_CR33","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1111\/j.1432-2277.2011.01256.x","volume":"24","author":"TM Manzia","year":"2011","unstructured":"Manzia TM, Bellini MI, Corona L, Toti L, Fratoni S, Cillis A, et al. Successful treatment of systemic de novo sarcoidosis with cyclosporine discontinuation and provision of rapamune after liver transplantation. Transpl Int. 2011;24(8):e69-70.","journal-title":"Transpl Int"},{"issue":"2","key":"10700_CR34","doi-asserted-by":"publisher","first-page":"e-81-91","DOI":"10.1016\/S2665-9913(23)00302-8","volume":"6","author":"A Redl","year":"2024","unstructured":"Redl A, Doberer K, Unterluggauer L, Kleissl L, Krall C, Mayerhofer C, et al. Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial. Lancet Rheumatol. 2024;6(2):e-81-91.","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10700_CR35","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04079-2020","volume":"58","author":"RP Baughman","year":"2021","unstructured":"Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58(6):2004079.","journal-title":"Eur Respir J"},{"issue":"3","key":"10700_CR36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40272-019-00337-7","volume":"21","author":"M Bevacqua","year":"2019","unstructured":"Bevacqua M, Baldo F, Pastore S, Valencic E, Tommasini A, Maestro A, et al. Off-label use of sirolimus and everolimus in a pediatric center: a case series and review of the literature. Paediatr Drugs. 2019;21(3):185\u201393.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"10700_CR37","doi-asserted-by":"publisher","first-page":"20230652","DOI":"10.1515\/med-2023-0652","volume":"18","author":"N Treder","year":"2023","unstructured":"Treder N, Plenis A, Maliszewska O, Kaczmarczyk N, Oledzka I, Kowalski P, et al. Monitoring of sirolimus in the whole blood samples from pediatriac patients with lymphatic anomalies. Open Med (Wars). 2023;18(1):20230652.","journal-title":"Open Med (Wars)"},{"key":"10700_CR38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4103\/jrms.jrms_531_22","volume":"28","author":"S Shahidi","year":"2023","unstructured":"Shahidi S, Vahdat S, Atatpour A, Meshkinfar S. The side effect profile of sirolimus and its relationship with some variables. A retrospective study of Iranian renal transplant patients. J Res Med Sci. 2023;28:58.","journal-title":"J Res Med Sci"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10700-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-025-10700-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10700-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T14:20:05Z","timestamp":1765549205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-025-10700-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10700"],"URL":"https:\/\/doi.org\/10.1007\/s12265-025-10700-4","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The review article involved no human participants or animal experimentation. No ethics approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The authors have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}}]}}